UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
Motif ? one of the clinical trial technology market's fastest growing companies ? continues contributing to major innovations in how clinical trial patient data are collected, with Chief Scientific ...
MedPage Today on MSN
Novel pills promising in relapsed/refractory multiple myeloma
Could a new class of oral drugs be game changers?
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Beam Therapeutics Inc. has raked in $255 million in cash from the sale of its spinout, Orbital Therapeutics, to Bristol Myers ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
4don MSN
Outgoing GSK boss Emma Walmsley says US is 'best place to invest' in parting shot at UK pharma
GSK and UK-based rival AstraZeneca have revealed billions of dollars in US investment in recent months in response to ...
Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology ...
hubXchange’s Antibody Therapeutics Xchange Boston 2026 brings together senior-level scientists, R&D leaders, and executives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback